Bd partners with camtech health to increase access to cervical cancer screening in singapore

First-ever program in the country to offer at-home self-collection of samples for hpv testing singapore , feb. 21, 2024 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced a strategic partnership with camtech health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in singapore to self-collect a sample in the privacy of their own home. the program combines the camtech health hpv (human papillomavirus) test for self-collection with the bd onclarity™ hpv assay, which is a clinically validated test that can simultaneously detect 14 high-risk hpv strains (or "genotypes").
BDX Ratings Summary
BDX Quant Ranking